ADUS vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ADUS exhibits mixed financial health with a Piotroski F-Score of 4/9, indicating a weak to stable foundation, and no Altman Z-Score available, which limits distress risk assessment. The stock trades at $101.35, below its intrinsic value of $153.99 and Graham Number of $83.83, suggesting potential undervaluation on a defensive basis. However, strong revenue and earnings growth (25.6% and 52.1% YoY) are tempered by bearish insider activity and a lack of dividend. Analysts maintain a 'buy' recommendation with a target of $140.23, reflecting optimism in future performance.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ADUS vs MRK: Head-to-Head Comparison
This page compares Addus HomeCare Corporation (ADUS) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.